<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939753</url>
  </required_header>
  <id_info>
    <org_study_id>Sevoflu-DI-IZ</org_study_id>
    <nct_id>NCT04939753</nct_id>
  </id_info>
  <brief_title>Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis</brief_title>
  <official_title>Incidence of Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the Intensive Care Unit: a Retrospective Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to retrospectively explore the electronic medical records of all&#xD;
      patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the last 10&#xD;
      years (March 1st 2011- March 1st 2021) and who received prolonged sedation (&gt;24h) with&#xD;
      sevoflurane.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nephrogenic Diabetes Insipidus prevalence</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>How many patients under sevoflurane sedation ultimately develop NDI? NDI confirmed by demonstrating the absence of a urine concentrating response to exogenous Arginine Vasopressine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients that develop risk factors of NDI</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Number of patients that develop risk factors (electrolyte disorder, urinary obstruction) for NDI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of time patient was placed under sevoflurane sedation.</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>How long are they under sevoflurane sedation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with electrolyte abnormalities as assessed by lab results.</measure>
    <time_frame>during hospitalization, up to 8 weeks.</time_frame>
    <description>Lab results of hematology and chemistry labs show an electrolyte imbalance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with excessive urine output</measure>
    <time_frame>during hospitalization, up to 8 weeks.</time_frame>
    <description>Amount of urine output: &gt;40 ml/kg/24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with an abnormal physical examination.</measure>
    <time_frame>during hospitalization, up to 8 weeks.</time_frame>
    <description>Typical physical symptoms of (N)DI: tired, lethargic, tachycardia, tachypnea, hypotension and dry mucous membranes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with urine with an abnormal osmolality</measure>
    <time_frame>during hospitalization, up to 8 weeks.</time_frame>
    <description>Lab testing of urine: osmolality &lt; 300 mosm/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that show an abnormal amount of fluid intake</measure>
    <time_frame>during hospitalization, up to 8 weeks.</time_frame>
    <description>&gt;2.5l/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that have an abnormal abdominal echo of the bladder.</measure>
    <time_frame>during hospitalization, up to 8 weeks.</time_frame>
    <description>Echo shows an enlarged bladder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of symptoms of NDI</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Number of symptoms of NDI do these patients show?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of symptoms of NDI</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>After how much time do these patients show symptoms of NDI?</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Nephrogenic Diabetes Insipidus</condition>
  <arm_group>
    <arm_group_label>Sevoflurane group</arm_group_label>
    <description>Patients that received sevoflurane while in ICU care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sevoflurane administration to sedate the patient</description>
    <arm_group_label>Sevoflurane group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients who were admitted to the Intensive Care Unit (ICU) of the UZ Brussels in the&#xD;
        last 10 years (March 1st 2011- March 1st 2021) and who received prolonged sedation (&gt;24h)&#xD;
        with sevoflurane.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sevoflurane administration &gt;24h&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years old&#xD;
&#xD;
          -  Pre-existing diabetes insipidus&#xD;
&#xD;
          -  Use of drugs at risk for diabetes insipidus (including lithium, cisplatin)&#xD;
&#xD;
          -  Hypercalcemia (persistently &gt;2.75 mmol/L)&#xD;
&#xD;
          -  Pituitary or acute brain surgery&#xD;
&#xD;
          -  Patients requiring continuous renal replacement therapy&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Evelien Vandeurzen, Master</last_name>
    <phone>024749237</phone>
    <email>evelien.vandeurzen@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelien Vandeurzen, Biomedical Sciences</last_name>
      <phone>024749237</phone>
      <email>evelien.vandeurzen@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Josia Glissenaar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bastiaan Sol, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bert Bravenboer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silke Verheyen, Pharmacist</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeroen de Filette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Poelaert, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Insipidus</mesh_term>
    <mesh_term>Diabetes Insipidus, Nephrogenic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

